Generate Biomedicines: $1.2B valuation, IPO Readiness 35, Series A. AI-first drug company using generative biology to design novel protein therapeutics. Track live on The IPO Stack.
AI-first drug company using generative biology to design novel protein therapeutics.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Generate Biomedicines IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Generate Biomedicines has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Generate Biomedicines is valued at $1.2B as of December 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Generate Biomedicines shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Generate Biomedicines scores 35/100 (Grade: F) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Generate Biomedicines has raised $150M in total venture capital and private equity funding, with backing from ARCH Venture Partners, Foresite Capital, T. Rowe Price.
Generate Biomedicines's notable investors include ARCH Venture Partners, Foresite Capital, T. Rowe Price. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Generate Biomedicines is a Biotechnology company. AI-first drug company using generative biology to design novel protein therapeutics.